Diabetes is a chronic condition that affects millions of people worldwide. In an area where therapeutic treatments and approaches are evolving rapidly, the personalization of diabetes management is becoming increasingly important. Diabeta, the platform dedicated to health professionals, plays a key role in this process, providing the tools and resources needed to ensure personalized and effective management of diabetes.
The importance of personalized diabetes management
Diabetes does not affect all people in the same way. Each patient has individual needs and conditions that require personalized approaches. According to statistics, approximately 451 million people worldwide suffer from diabetes, and this number is estimated to reach 693 million by 2045, according to the International Federation of Diabetes (IDF). This diversity in the manifestations and impact of the disease emphasizes the importance of management adapted to each individual.
Quick access to updated guides and recommendations
Diabeta provides instant access to the latest treatment guides and clinical recommendations. These resources are essential for doctors because they allow treatment to be adjusted according to the latest discoveries and standards of care. In a study by the American Diabetes Association, it was found that the use of updated guidelines can significantly reduce the complications associated with diabetes.
Diabeta is a valuable tool in optimizing the personalized management of diabetes, providing essential resources and innovative tools that support both health professionals and patients. Through access to up-to-date information, treatment customization tools and educational resources, Diabeta contributes significantly to improving patient care and optimizing therapeutic results.
Diabeta was developed by a Romanian company, Apollo Technologies, specialized in creating professional applications based on artificial intelligence. The application is made available to doctors in professional medical communities administered by People and Companies, with the support of the partners Novo Nordisk, Boehringer Ingelheim and Medtronic.
